
Annual report 2025
added 03-12-2026
Repro Med Systems Net Income 2011-2026 | KRMD
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Repro Med Systems
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.64 M | -6.07 M | -13.7 M | -8.66 M | -4.56 M | -1.18 M | 564 K | 911 K | -535 K | 783 K | 753 K | 703 K | 726 K | 816 K | 704 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 911 K | -13.7 M | -2.09 M |
Quarterly Net Income Repro Med Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -778 K | -207 K | -1.17 M | - | -1.58 M | -989 K | -1.94 M | - | -1.37 M | -2.5 M | -2.41 M | - | -1.23 M | -2.92 M | -2.54 M | - | -1.09 M | -1.12 M | -1.28 M | - | 249 K | -1.08 M | 449 K | - | 652 K | 78.2 K | -85.4 K | - | 387 K | 476 K | 403 K | - | 266 K | 148 K | 127 K | -104 K | -153 K | -320 K | - | 168 K | 438 K | 271 K | - | 92.7 K | 454 K | 361 K | - | 162 K | 326 K | 164 K | - | 55.5 K | 497 K | 441 K | - | 182 K | 498 K | 118 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 652 K | -2.92 M | -386 K |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical instruments industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AtriCure
ATRC
|
-11.4 M | $ 29.85 | 1.05 % | $ 1.43 B | ||
|
AngioDynamics
ANGO
|
-34 M | $ 10.6 | -1.03 % | $ 433 M | ||
|
Luminex Corporation
LMNX
|
15.2 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
-17.6 M | - | -9.52 % | $ 20.6 M | ||
|
Atrion Corporation
ATRI
|
19.4 M | - | - | $ 810 M | ||
|
Harvard Bioscience
HBIO
|
-3.42 M | $ 0.47 | -4.15 % | $ 19.9 M | ||
|
Alcon
ALC
|
376 M | $ 77.32 | -1.5 % | $ 40.4 B | ||
|
Antares Pharma, Inc.
ATRS
|
56.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
13.7 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
-24.5 M | - | - | $ 282 M | ||
|
ICU Medical
ICUI
|
732 K | $ 125.85 | -2.28 % | $ 3.1 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
223 M | - | -0.05 % | $ 10.3 B | ||
|
InfuSystem Holdings
INFU
|
18 K | $ 9.31 | -0.85 % | $ 192 M | ||
|
iRhythm Technologies
IRTC
|
-44.6 M | $ 113.0 | -1.46 % | $ 3.62 B | ||
|
Intuitive Surgical
ISRG
|
2.86 B | $ 472.16 | -1.48 % | $ 169 B | ||
|
The Cooper Companies
COO
|
375 M | $ 69.92 | -2.24 % | $ 13.9 B | ||
|
Varian Medical Systems, Inc.
VAR
|
292 M | - | -0.02 % | $ 16.3 B | ||
|
Glaukos Corporation
GKOS
|
-135 M | $ 97.02 | -0.79 % | $ 4.7 B | ||
|
Becton, Dickinson and Company
BDX
|
1.68 B | $ 159.36 | -0.17 % | $ 45.8 B | ||
|
Haemonetics Corporation
HAE
|
168 M | $ 59.92 | 0.72 % | $ 3.02 B | ||
|
electroCore
ECOR
|
-18.8 M | $ 6.14 | -3.0 % | $ 33.9 K | ||
|
Masimo Corporation
MASI
|
-305 M | $ 175.49 | -0.01 % | $ 9.35 B | ||
|
Isoray
ISR
|
-79.3 M | - | 0.03 % | $ 108 M | ||
|
Predictive Oncology
POAI
|
-12.7 M | - | - | $ 31.1 M | ||
|
Ekso Bionics Holdings
EKSO
|
-11.7 M | $ 11.56 | -2.12 % | $ 28 M | ||
|
Baxter International
BAX
|
-957 M | $ 17.4 | -3.36 % | $ 8.93 B | ||
|
BioLife Solutions
BLFS
|
-20.2 M | $ 18.36 | 1.16 % | $ 846 M | ||
|
Nephros
NEPH
|
-1.58 M | $ 3.5 | -7.89 % | $ 36.4 M | ||
|
ResMed
RMD
|
779 M | $ 230.84 | -0.68 % | $ 33.7 B | ||
|
Retractable Technologies
RVP
|
-11.9 M | $ 0.71 | 2.62 % | $ 21.3 M | ||
|
NeuroMetrix
NURO
|
-7.81 M | - | 5.05 % | $ 9.02 M | ||
|
Merit Medical Systems
MMSI
|
128 M | $ 69.95 | 2.61 % | $ 4.14 B | ||
|
Envista Holdings Corporation
NVST
|
47 M | $ 24.61 | -3.26 % | $ 4.13 B | ||
|
STAAR Surgical Company
STAA
|
-80.4 M | $ 18.84 | 2.45 % | $ 934 M | ||
|
Stereotaxis
STXS
|
-21.6 M | $ 1.89 | 0.27 % | $ 172 M | ||
|
Teleflex Incorporated
TFX
|
-714 M | $ 107.32 | -0.87 % | $ 4.79 B | ||
|
OraSure Technologies
OSUR
|
-68.7 M | $ 2.97 | -3.88 % | $ 218 M | ||
|
LeMaitre Vascular
LMAT
|
57.7 M | $ 108.06 | 1.43 % | $ 2.45 B | ||
|
Utah Medical Products
UTMD
|
4.29 M | $ 63.28 | 1.02 % | $ 230 M | ||
|
Pro-Dex
PDEX
|
8.98 M | $ 48.46 | 3.5 % | $ 159 M | ||
|
Microbot Medical
MBOT
|
-10.7 M | $ 2.69 | -1.47 % | $ 27.4 M | ||
|
West Pharmaceutical Services
WST
|
494 M | $ 235.46 | 1.89 % | $ 17 B | ||
|
Repligen Corporation
RGEN
|
35.6 M | $ 114.2 | 0.39 % | $ 6.36 M | ||
|
DENTSPLY SIRONA
XRAY
|
-598 M | $ 11.54 | -2.2 % | $ 2.3 B | ||
|
Pulse Biosciences
PLSE
|
-72.8 M | $ 21.57 | 1.27 % | $ 1.45 B | ||
|
STERIS plc
STE
|
615 M | $ 214.57 | 1.05 % | $ 21.2 B | ||
|
Milestone Scientific
MLSS
|
-4.71 M | $ 0.28 | -3.75 % | $ 22.3 M |